ZC

Zach Collins

Partner at Mission BioCapital

San Francisco Bay Area

Overview 

Zach Collins is a Partner at Mission BioCapital, with a background in molecular biology and a Ph.D. from Harvard University. He has held roles such as Chief Business Officer at Alessa Therapeutics, Inc. and has experience in project management, research, and teaching in the life sciences field. Collins has a strong track record of success in the biotech sector, having transitioned from roles as a Graduate Student Researcher to Partner at Mission BioCapital, where he focuses on investing in diverse founders and companies at various stages, particularly in the San Francisco Bay Area.

Work Experience 

  • Partner

    2024 - Current

  • Principal

    2021 - 2024

  • Associate

    2019 - 2021

  • Analyst

    2018 - 2019

Mission BioCapital is a life science venture capital firm that invests in early-stage companies.

Raised $11,000,001.00.

  • Entrepreneur Success Partner

    2020

MBC BioLabs is the premier biotech incubator in the Bay Area.

  • Chief Business Officer

    2022

Alessa Therapeutics develops localized treatments for solid organ disease.

Raised $6,264,997.00 from Mission BioCapital.

  • Board Observer

    2021

Nuvig Therapeutics is a biotechnology company developing therapies to induce natural mechanisms to restore immune homeostasis.

Raised $208,000,000.00 from Norwest Venture Partners, Blue Owl, Mission BioCapital, Lotte, Cowen Healthcare Investments, Bristol-Myers Squibb, Alexandria Venture Investments, Sanofi Ventures, Global BioAccess Fund and Abrdn.

  • Board Obsever

    2021

  • Postdoctoral Research Fellow

    2018 - 2018

  • Graduate Student Researcher

    2013 - 2018

    • Uncovered a novel genetic feedback mechanism regulating the differentiation of neural stem cells • Designed and developed CRISPR Cas9 based genome engineering techniques • Collaborated on research projects using cutting edge light-sheet microscopy and single cell genomics

  • Team Member

    2017 - 2018

    • Performed market research for a CAR T-cell therapy being developed at the Dana-Farber Cancer Institute • Presented due-diligence and regulatory strategy findings to a team of scientists and entrepreneurs

  • Undergraduate Research Program Student

    2012 - 2012

Articles About Zach

Relevant Websites